Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA)

Prostate

Volumn 74, Issue 16, 2014, Pages 1674-1690

  Tykvart, J ^a,b   Navratil V ^a,b   Sedlak F ^a,b   Corey, E ^c   Colombatti, M ^d   Fracasso, G ^d   Koukolik F ^e   Barinka C ^f   Sacha P ^a,b   Konvalinka, J ^a,b  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VERONA   (Italy)

^e Thomayer Teaching Hospital   (Czech Republic)

^f INSTITUTE OF BIOTECHNOLOGY   (Czech Republic)

Author keywords

ELISA; flow cytometry; folate hydrolase; glutamate carboxypeptidase II; immunohistochemistry; NAALADase; prostate specific membrane antigen; surface plasmon resonance; Western blot

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 107 1A4; MONOCLONAL ANTIBODY 2G7; MONOCLONAL ANTIBODY 3E6; MONOCLONAL ANTIBODY D2B; MONOCLONAL ANTIBODY GCP 02; MONOCLONAL ANTIBODY GCP 04; MONOCLONAL ANTIBODY GCP 05; MONOCLONAL ANTIBODY J415; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY YPSMA 1; MONOCLONAL ANTIBODY YPSMA 2; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; PROSTATE SPECIFIC ANTIGEN;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SURFACE PLASMON RESONANCE; WESTERN BLOTTING; ADENOCARCINOMA; DIAGNOSTIC USE; EPITOPE MAPPING; IMMUNOLOGY; METABOLISM; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84921984984     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22887     Document Type: Article

References (69)

1. Ghosh A, Heston WD,. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91 (3): 528-539.
2. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH,. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57 (17): 3629-3634.
3. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C,. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3 (1): 81-85.
4. Foss CA, Mease RC, Cho SY, Kim HJ, Pomper MG,. GCPII imaging and cancer. Curr Med Chem 2012; 19 (9): 1346-1359.
5. Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, Konvalinka J, Hilgenfeld R,. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J 2006; 25 (6): 1375-1384.
6. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH,. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998; 58 (18): 4055-4060.
7. Javier DJ, Nitin N, Levy M, Ellington A, Richards-Kortum R,. Aptamer-targeted gold nanoparticles as molecular-specific contrast agents for reflectance imaging. Bioconjug Chem 2008; 19 (6): 1309-1312.
8. Kasten BB, Liu T, Nedrow-Byers JR, Benny PD, Berkman CE,. Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles. Bioorg Med Chem Lett 2013; 23 (2): 565-568.
9. Schol D, Fleron M, Greisch JF, Jaeger M, Frenz M, De Pauw E, De Pauw-Gillet MC,. Anti-PSMA antibody-coupled gold nanorods detection by optical and electron microscopies. Micron 2013; 50: 68-74.
10. Wang L, Li L, Guo Y, Tong H, Fan X, Ding J, Huang H,. Construction and in vitro/in vivo targeting of PSMA-targeted nanoscale microbubbles in prostate cancer. Prostate 2013; 73 (11): 1147-1158.
11. Xu W, Siddiqui IA, Nihal M, Pilla S, Rosenthal K, Mukhtar H, Gong S,. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials 2013; 34 (21): 5244-5253.
12. Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST,. Prostate-specific membrane antigen-based imaging. Urol Oncol 2013; 31 (2): 144-154.
13. Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L,. Trial watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3 (1): e27048.
14. Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L,. Trial watch: Anticancer radioimmunotherapy. Oncoimmunology 2013; 2 (9): e25595.
15. Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L,. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2 (1): e22789.
16. Al-Ahmadie HA, Olgac S, Gregor PD, Tickoo SK, Fine SW, Kondagunta GV, Scher HI, Morris MJ, Russo P, Motzer RJ, Reuter VE,. Expression of prostate-specific membrane antigen in renal cortical tumors. Mod Pathol 2008; 21 (6): 727-732.
17. Baccala A, Sercia L, Li J, Heston W, Zhou M,. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 2007; 70 (2): 385-390.
18. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB,. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59 (13): 3192-3198.
19. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC,. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res 1990; 50 (19): 6423-6429.
20. Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY, Haas GP,. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006; 30 (4): 628-636.
21. Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, Penetrante R,. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: An immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007; 50 (4): 472-483.
22. Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Muhlmann G, Ofner D, Zelger B, Ensinger C, Yang XJ, Geley S, Margreiter R, Bander NH,. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 2009; 40 (12): 1754-1761.
23. Rovenska M, Hlouchova K, Sacha P, Mlcochova P, Horak V, Zamecnik J, Barinka C, Konvalinka J,. Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. Prostate 2008; 68 (2): 171-182.
24. Troyer JK, Beckett ML, Wright GL Jr., Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995; 62 (5): 552-558.
25. Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer LS,. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. Prostate 2000; 43 (2): 150-157.
26. Ellis RJ, Kaminsky DA, Zhou EH, Fu P, Chen WD, Brelin A, Faulhaber PF, Bodner D,. Ten-year outcomes: The clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011; 81 (1): 29-34.
27. Han M, Partin AW,. Current clinical applications of the in-capromab pendetide scan (prostascint(r) scan, cyt-356). Rev Urol 2001; 3 (4): 165-171.
28. Hinkle GH, Burgers JK, Neal CE, Texter JH, Kahn D, Williams RD, Maguire R, Rogers B, Olsen JO, Badalament RA,. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998; 83 (4): 739-747.
29. Horoszewicz JS, Kawinski E, Murphy GP,. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7 (5B): 927-935.
30. Troyer JK, Feng Q, Beckett ML, Wright GL Jr., Biochemical characterization and mapping of the 7E11-C5. 3 epitope of the prostate-specific membrane antigen. Urol Oncol 1995; 1 (1): 29-37.
31. Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM,. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 2013; 19 (18): 5182-5191.
32. Tagawa ST, Akhtar NH, Nikolopoulou A, Kaur G, Robinson B, Kahn R, Vallabhajosula S, Goldsmith SJ, Nanus DM, Bander NH,. Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer. Front Oncol 2013; 3: 214.
33. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS,. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010; 51 (8): 1293-1300.
34. Moffatt S, Papasakelariou C, Wiehle S, Cristiano R,. Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate. Gene Ther 2006; 13 (9): 761-772.
35. Patri AK, Myc A, Beals J, Thomas TP, Bander NH, Baker JR Jr., Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 2004; 15 (6): 1174-1181.
36. Kampmeier F, Williams JD, Maher J, Mullen GE, Blower PJ,. Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA). EJNMMI Res 2014; 4 (1): 13.
37. Bandekar A, Zhu C, Jindal R, Bruchertseifer F, Morgenstern A, Sofou S,. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular alpha-particle therapy of cancer. J Nucl Med 2014; 55 (1): 107-114.
38. Zhang F, Shan L, Liu Y, Neville D, Woo JH, Chen Y, Korotcov A, Lin S, Huang S, Sridhar R, Liang W, Wang PC,. An anti-PSMA bivalent immunotoxin exhibits specificity and efficacy for prostate cancer imaging and therapy. Adv Healthc Mater 2013; 2 (5): 736-744.
39. Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, Pullikuth A, Sui G, Sadelain M, Debinski W, Kulik G,. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia 2013; 15 (10): 1172-1183.
40. Lutje S, Rijpkema M, Franssen GM, Fracasso G, Helfrich W, Eek A, Oyen WJ, Colombatti M, Boerman OC,. Dual-modality image-guided surgery of prostate cancer with a radiolabeled fluorescent anti-psma monoclonal antibody. J Nucl Med 2014.
41. Colombatti M, Grasso S, Porzia A, Fracasso G, Scupoli MT, Cingarlini S, Poffe O, Naim HY, Heine M, Tridente G, Mainiero F, Ramarli D,. The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS One 2009; 4 (2): e4608.
42. Frigerio B, Fracasso G, Luison E, Cingarlini S, Mortarino M, Coliva A, Seregni E, Bombardieri E, Zuccolotto G, Rosato A, Colombatti M, Canevari S, Figini M,. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. Eur J Cancer 2013; 49 (9): 2223-2232.
43. Schmidt S, Fracasso G, Colombatti M, Naim HY,. Cloning and characterization of canine prostate-specific membrane antigen. Prostate 2013; 73 (6): 642-650.
44. Schmidt S, Gericke B, Fracasso G, Ramarli D, Colombatti M, Naim HY,. Discriminatory role of detergent-resistant membranes in the dimerization and endocytosis of prostate-specific membrane antigen. PLoS One 2013; 8 (6): e66193.
45. Lutje S, van Rij CM, Franssen GM, Fracasso G, Helfrich W, Eek A, Oyen WJ, Colombatti M, Boerman OC,. Targeting human prostate cancer with In-labeled D2B IgG, F(ab') and Fab fragments in nude mice with PSMA-expressing xenografts. Contrast Media Mol Imaging 2014.
46. Brown LG, Wegner SK, Wang H, Buhler KR, Arfman EW, Lange PH, Vessella RL,. A novel monoclonal antibody 107-1A4 with high prostate specificity: Generation, characterization of antigen expression, and targeting of human prostate cancer xenografts. Prostate Cancer Prostatic Dis 1998; 1 (4): 208-215.
47. Wang S, Diamond DL, Hass GM, Sokoloff R, Vessella RL,. Identification of prostate specific membrane antigen (PSMA) as the target of monoclonal antibody 107-1A4 by proteinchip; array, surface-enhanced laser desorption/ionization (SELDI) technology. Int J Cancer 2001; 92 (6): 871-876.
48. Mincheff M, Zoubak S, Altankova I, Tchakarov S, Makogonenko Y, Botev C, Ignatova I, Dimitrov R, Madarzhieva K, Hammett M, Pomakov Y, Meryman H, Lissitchkov T,. Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes. Cancer Gene Ther 2003; 10 (12): 907-917.
49. Chaux A, Eifler J, Karram S, Al-Hussain T, Faraj S, Pomper M, Rodriguez R, Netto GJ,. Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: Implications for novel intraoperative PSMA-based fluorescent imaging techniques. Urol Oncol 2013; 31 (5): 572-575.
50. Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, Huland H, Bokemeyer C, Yekebas E, Dierlamm J, Balabanov S, Kilic E, Wilczak W, Simon R, Sauter G, Schlomm T,. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 2011; 71 (3): 281-288.
51. Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA,. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007; 38 (5): 696-701.
52. Murphy GPS, WA), Boynton, Alton L. (Redmond, WA), Holmes, Eric H. (Bothell, WA), Tino, William Thomas (Redmond, WA); Northwest Biotherapeutics, Inc. (Seattle, WA), assignee. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. United States. 2000.
53. Knedlik T, Navratil V, Vik V, Pacik D, Sacha P, Konvalinka J,. Detection and quantitation of glutamate carboxypeptidase II in human blood. Prostate 2014.
54. Kinoshita Y, Kuratsukuri K, Newman N, Rovito PM, Kaumaya PT, Wang CY, Haas GP,. Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer. Prostate Cancer Prostatic Dis 2005; 8 (4): 359-363.
55. Barinka C, Mlcochova P, Sacha P, Hilgert I, Majer P, Slusher BS, Horejsi V, Konvalinka J,. Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding. Eur J Biochem 2004; 271 (13): 2782-2790.
56. Barinka C, Sacha P, Sklenar J, Man P, Bezouska K, Slusher BS, Konvalinka J,. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci 2004; 13 (6): 1627-1635.
57. Sacha P, Zamecnik J, Barinka C, Hlouchova K, Vicha A, Mlcochova P, Hilgert I, Eckschlager T, Konvalinka J,. Expression of glutamate carboxypeptidase II in human brain. Neuroscience 2007; 144 (4): 1361-1372.
58. Wang X, Ma D, Olson WC, Heston WD,. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther 2011; 10 (9): 1728-1739.
59. Chen Z, Penet MF, Nimmagadda S, Li C, Banerjee SR, Winnard PT Jr, Artemov D, Glunde K, Pomper MG, Bhujwalla ZM,. PSMA-targeted theranostic nanoplex for prostate cancer therapy. ACS Nano 2012; 6 (9): 7752-7762.
60. Mlcochova P, Barinka C, Tykvart J, Sacha P, Konvalinka J,. Prostate-specific membrane antigen and its truncated form PSM'. Prostate 2009; 69 (5): 471-479.
61. Elsasser-Beile U, Wolf P, Gierschner D, Buhler P, Schultze-Seemann W, Wetterauer U,. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 2006; 66 (13): 1359-1370.
62. Schulke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM, Arrigale RR, Zhan C, Chodera AJ, Surowitz KG, Maddon PJ, Heston WD, Olson WC,. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A 2003; 100 (22): 12590-12595.
63. Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, Maddon PJ, Olson WC,. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006; 12 (8): 2591-2596.
64. Tykvart J, Sacha P, Barinka C, Knedlik T, Starkova J, Lubkowski J, Konvalinka J,. Efficient and versatile one-step affinity purification of in vivo biotinylated proteins: Expression, characterization and structure analysis of recombinant human glutamate carboxypeptidase II. Protein Expr Purif 2012; 82 (1): 106-115.
65. Hegnerova K, Bockova M, Vaisocherova H, Kristofikova Z, Ricny J, Ripova D, Homola J,. Surface plasmon resonance biosensors for detection of Alzheimer disease biomarker. Sensor Actuat B-Chem 2009; 139 (1): 69-73.
66. Pimkova K, Bockova M, Hegnerova K, Suttnar J, Cermak J, Homola J, Dyr JE,. Surface plasmon resonance biosensor for the detection of VEGFR-1-a protein marker of myelodysplastic syndromes. Anal Bioanal Chem 2012; 402 (1): 381-387.
67. Barinka C, Rinnova M, Sacha P, Rojas C, Majer P, Slusher BS, Konvalinka J,. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem 2002; 80 (3): 477-487.
68. Liu N, Liang W, Ma X, Li X, Ning B, Cheng C, Ou G, Wang B, Zhang J, Gao Z,. Simultaneous and combined detection of multiple tumor biomarkers for prostate cancer in human serum by suspension array technology. Biosens Bioelectron 2013; 47: 92-98.
69. Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH,. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 2006; 26 (14): 5310-5324.